Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJ, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz HJ.

J Clin Oncol. 2016 Jan 10;34(2):144-50. doi: 10.1200/JCO.2015.61.6441. Epub 2015 Oct 26.

2.

Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.

van Rooijen KL, Shi Q, Goey KKH, Meyers J, Heinemann V, Diaz-Rubio E, Aranda E, Falcone A, Green E, de Gramont A, Sargent DJ, Punt CJA, Koopman M.

Eur J Cancer. 2018 Mar;91:99-106. doi: 10.1016/j.ejca.2017.12.014. Epub 2018 Jan 30.

PMID:
29353165
3.

Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.

Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent DJ, Eckhardt SG, Eng C; Aide et Recherche en Cancérologie Digestive Foundation.

J Clin Oncol. 2014 Sep 20;32(27):2975-84.

4.

Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies.

Patel GS, Ullah S, Beeke C, Hakendorf P, Padbury R, Price TJ, Karapetis CS.

Cancer Med. 2015 Oct;4(10):1461-71. doi: 10.1002/cam4.490. Epub 2015 Jul 25.

5.

Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.

Song A, Eo W, Lee S.

World J Gastroenterol. 2015 Nov 21;21(43):12410-20. doi: 10.3748/wjg.v21.i43.12410.

6.

Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer.

Blauwhoff-Buskermolen S, Versteeg KS, de van der Schueren MA, den Braver NR, Berkhof J, Langius JA, Verheul HM.

J Clin Oncol. 2016 Apr 20;34(12):1339-44. doi: 10.1200/JCO.2015.63.6043. Epub 2016 Feb 22.

PMID:
26903572
7.

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.

Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJ, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, Díaz-Rubio E, Porschen R, Tebbutt NC, Fuchs C, Souglakos J, Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent DJ.

J Clin Oncol. 2015 Jan 1;33(1):22-8. doi: 10.1200/JCO.2014.56.5887. Epub 2014 Nov 10.

8.

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E.

Lancet Oncol. 2015 Aug;16(8):937-48. doi: 10.1016/S1470-2045(15)00138-2. Epub 2015 Jul 13.

PMID:
26184520
9.

Is obesity an advantage in patients with colorectal cancer?

Kasi PM, Zafar SY, Grothey A.

Expert Rev Gastroenterol Hepatol. 2015;9(11):1339-42. doi: 10.1586/17474124.2015.1089170. Epub 2015 Sep 14. Review.

PMID:
26366838
10.

Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.

Piessevaux H, Buyse M, Schlichting M, Van Cutsem E, Bokemeyer C, Heeger S, Tejpar S.

J Clin Oncol. 2013 Oct 20;31(30):3764-75. doi: 10.1200/JCO.2012.42.8532. Epub 2013 Sep 16.

PMID:
24043732
11.

Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy.

Faruk Aykan N, Yildiz I, Sen F, Kilic L, Keskin S, Ciftci R, Karabulut S, Sakar B, Disci R.

Med Oncol. 2013;30(3):679. doi: 10.1007/s12032-013-0679-4. Epub 2013 Aug 7.

12.

Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer.

Shah MS, Fogelman DR, Raghav KP, Heymach JV, Tran HT, Jiang ZQ, Kopetz S, Daniel CR.

Cancer. 2015 Sep 1;121(17):2968-75. doi: 10.1002/cncr.29440. Epub 2015 May 14.

13.

[Evaluation of thrombocytosis as predictive factor in colorectal cancer].

Baranyai Z, Jósa V, Krzystanek M, Eklund AC, Szász AM, Szállási Z.

Magy Seb. 2013 Dec;66(6):331-7. doi: 10.1556/MaSeb.66.2013.6.5. Hungarian.

PMID:
24333978
14.

Primary tumor location as a prognostic factor in metastatic colorectal cancer.

Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, Maus MK, Antoniotti C, Langer C, Scherer SJ, Müller T, Hurwitz HI, Saltz L, Falcone A, Lenz HJ.

J Natl Cancer Inst. 2015 Feb 24;107(3). pii: dju427. doi: 10.1093/jnci/dju427. Print 2015 Mar.

15.

Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients.

Lee DW, Han SW, Cha Y, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Park JW, Ryoo SB, Jeong SY, Kang GH, Park KJ, Kim TY.

BMC Cancer. 2015 Oct 14;15:690. doi: 10.1186/s12885-015-1704-0.

16.

Lower body mass index predicts worse cancer-specific prognosis in octogenarians with colorectal cancer.

Adachi T, Hinoi T, Kinugawa Y, Enomoto T, Maruyama S, Hirose H, Naito M, Tanaka K, Miyake Y, Watanabe M.

J Gastroenterol. 2016 Aug;51(8):779-87. doi: 10.1007/s00535-015-1147-z. Epub 2015 Dec 10.

PMID:
26660524
17.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

Aparicio T, Ducreux M, Faroux R, Barbier E, Manfredi S, Lecomte T, Etienne PL, Bedenne L, Bennouna J, Phelip JM, François E, Michel P, Legoux JL, Gasmi M, Breysacher G, Rougier P, De Gramont A, Lepage C, Bouché O, Seitz JF; for FFCD investigators.

Eur J Cancer. 2018 Jul;98:1-9. doi: 10.1016/j.ejca.2018.03.031. Epub 2018 May 26.

18.

Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.

Song QB, Wang Q, Hu WG.

World J Gastroenterol. 2015 Apr 14;21(14):4365-72. doi: 10.3748/wjg.v21.i14.4365. Review.

19.

Low, rather than high, body mass index confers increased risk for post-liver transplant death and graft loss: Risk modulated by model for end-stage liver disease.

Bambha KM, Dodge JL, Gralla J, Sprague D, Biggins SW.

Liver Transpl. 2015 Oct;21(10):1286-94. doi: 10.1002/lt.24188.

20.

Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.

Tsai HL, Lin CH, Huang CW, Yang IP, Yeh YS, Hsu WH, Wu JY, Kuo CH, Tseng FY, Wang JY.

Int J Clin Exp Pathol. 2015 Feb 1;8(2):1900-10. eCollection 2015.

Supplemental Content

Support Center